TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
33 hedge funds and large institutions have $29.8M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
33% more capital invested
Capital invested by funds: $22.5M → $29.8M (+$7.33M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 32 → 33 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Puissance Capital Management
New York
|
+$9.17M |
| 2 |
LA
Linden Advisors
New York
|
+$7.75M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.93M |
| 4 |
Renaissance Technologies
New York
|
+$673K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$253K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.02M |
| 2 |
QF
QVT Financial
New York
|
-$216K |
| 3 |
XSC
X-Square Capital
Guaynabo,
Puerto Rico
|
-$139K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$66K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$39K |
TCON Hedge Fund Activity: Q1 2018 in Review
33 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2018, worth a combined $29.8M — up 33% from $22.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TCON positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Puissance Capital Management, opening a new position worth an estimated $9.17M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $3.02M sold.
- 33 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2018, up from 32 in Q4 2017.
- Funds reported $29.8M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2018, up 33% quarter-over-quarter.
- 7 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 6 closed out, a net change of +1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was Puissance Capital Management, an estimated $9.17M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Eventide Asset Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q1 2018.